Olverembatinib for FGFR1-rearranged Neoplasms

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 1, 2022

Primary Completion Date

August 31, 2024

Study Completion Date

August 31, 2027

Conditions

Myeloproliferative NeoplasmAcute Leukemia

Interventions

DRUG

Olverembatinib

Given PO

Trial Locations (1)

RECRUITING

First Affiliated Hospital of Soochow University, Suzhou

All Listed Sponsors

lead

The First Affiliated Hospital of Soochow University

OTHER